A Novel In Vitro Assay Correlates Insulin Receptor Autoantibodies With Fasting Insulin in Type B Insulin Resistance

Context Severe insulin resistance (IR) in the presence of insulin receptor autoantibodies (InsR-aAb) is known as type B insulin resistance (TBIR). Considerable progress in therapy has been achieved, but diagnosis and monitoring of InsR-aAb remains a challenge. Objective This work aimed to establish a robust in vitro method for InsR-Ab quantification. Methods Longitudinal serum samples from patients with TBIR at the National Institutes of Health were collected. A bridge-assay for InsR-aAb detection was established using recombinant human insulin receptor as bait and detector. Monoclonal antibodies served as positive controls for validation. Results The novel assay proved sensitive, robust, and passed quality control. The measured InsR-aAb from TBIR patients was associated with disease severity, decreased on treatment, and inhibited insulin signaling in vitro. Titers of InsR-aAb correlated positively to fasting insulin in patients. Conclusion Quantification of InsR-aAb from serum samples via the novel in vitro assay enables identification of TBIR and monitoring of successful therapy.

Automated summary

This study aimed to establish a robust in vitro method for quantification of insulin receptor autoantibodies (InsR-aAb). A bridge assay for the detection of InsR-aAb was established using recombinant human insulin receptor as bait and detector in longitudinal serum samples from TBIR patients. The novel assay proved to be sensitive, robust, and passed quality control, allowing for identification of TBIR and monitoring of successful therapy.